Sava Healthcare Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sava Healthcare Limited Pharmaceutical Export Portfolio Dataset — 22 Products, $11.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sava Healthcare Limited — Pharmaceutical Exporter Profile (2026) | 22 Products, $11.5M Trade | TransData Nexus

Sava Healthcare Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $11.5M Total Trade · DGFT Verified

Sava Healthcare Limited is an Indian pharmaceutical exporter with a total trade value of $11.5M across 22 products in 11 therapeutic categories. Based on 4,488 verified export shipments from Indian Customs (DGFT) records, Sava Healthcare Limited is the #1 Indian exporter in 2 products including Ivermectin, Asava. Top exports include Ivermectin ($2.3M), Apixaban ($1.4M), Bisoprolol ($1.1M).

Sava Healthcare Limited — Export Portfolio & Destination Treemap

Sava Healthcare Limited pharmaceutical export portfolio — 22 products across 11 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sava Healthcare Limited? — Company Overview & Market Position

Sava Healthcare Limited, established on 25 October 2004, is a public unlisted company headquartered in Wadhwan City, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U51397GJ2004PLC074963. As of the latest available data, Sava Healthcare has an authorized capital of ₹16.40 crore and a paid-up capital of ₹58.77 lakh. The company employs approximately 568 professionals. Sava Healthcare operates in the pharmaceutical sector, focusing on the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's website is www.savaglobal.com.

What Does Sava Healthcare Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ivermectin$2.3M 2Apixaban$1.4M

Product Portfolio — Top 22 by Export Value

Sava Healthcare Limited exports 22 pharmaceutical products across 11 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ivermectin	Antimalarial & Antiparasitic	$2.3M	346	27.0%	1
2	Apixaban	Cardiovascular	$1.4M	290	0.8%	12
3	Bisoprolol	Cardiovascular	$1.1M	47	1.3%	10
4	Fluticasone	Respiratory	$1.1M	711	0.5%	5
5	Glucosamine	Nutritional Supplements	$868.3K	24	6.6%	6
6	Ambroxol	Respiratory & OTC	$818.9K	23	5.5%	5
7	Dapagliflozin	Advanced Diabetes Medications	$681.6K	535	1.4%	15
8	Salmeterol	Respiratory	$614.7K	586	0.8%	6
9	Empagliflozin	Diabetes & Endocrine	$569.5K	495	8.5%	4
10	Extract	Ayurvedic & Herbal Products	$477.2K	125	3.9%	7
11	Pyrantel	Antimalarial & Antiparasitic	$382.1K	47	11.7%	4
12	Valacyclovir	Antivirals	$243.8K	157	0.3%	10
13	Asava	Ayurvedic & Herbal Products	$205.0K	9	44.8%	1
14	Torsemide	Diuretics	$165.8K	307	0.9%	8
15	Tiotropium	Respiratory	$131.7K	12	0.2%	5
16	Semaglutide	Advanced Diabetes Medications	$117.4K	60	2.4%	9
17	Formoterol	Respiratory	$117.1K	323	0.2%	12
18	Melatonin	Nutritional Supplements	$48.8K	147	0.5%	15
19	Canagliflozin	Advanced Diabetes Medications	$21.9K	98	2.5%	8
20	Acarbose	Advanced Diabetes Medications	$14.1K	83	0.2%	12
21	Saxagliptin	Advanced Diabetes Medications	$3.4K	54	0.1%	8
22	Catheter	Medical Devices & Diagnostics	$1.0K	9	0.9%	8

Sava Healthcare Limited exports 22 pharmaceutical products across 11 therapeutic categories with a total export value of $11.5M. The company is the #1 Indian exporter in 2 products: Ivermectin, Asava. The top category is Antimalarial & Antiparasitic (23.7% of portfolio), followed by Cardiovascular (22.5%), reflecting a diversified portfolio where the top 5 products account for only 59.8% of total value.

Sava Healthcare Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sava Healthcare Limited operates a WHO-GMP and PIC/s approved manufacturing plant located in Surendranagar, Gujarat. This facility specializes in the production of nasal drug delivery platforms, including nasal sprays and dry powder inhalers. The plant is strategically situated approximately 2.5 hours from Ahmedabad, facilitating efficient distribution. Additionally, the company is in the process of establishing a USFDA-accredited plant near Indore, India, to further enhance its manufacturing capabilities.

3Key Leadership

The leadership team at Sava Healthcare Limited includes:

Vishal Ramchandra Jadhav: Director
Vinod Ramchandra Jadhav: Director
Sonal Sisodia: Director
Ulhas Rajaram Puranik: Additional Director
Renu Prashant Anjanikar: Additional Director
Sunil Kumar Bajaj: Additional Director

These individuals play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sava Healthcare Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sava Healthcare Limited has made significant strides in regulated markets, particularly in the United States. The company is in the process of establishing a USFDA-accredited manufacturing plant near Indore, India, aiming to enhance its presence in the U.S. market. While specific details regarding regulatory filings and approvals in the European Union, United Kingdom, and Australia are not readily available, the company's adherence to WHO-GMP and PIC/s standards suggests a commitment to meeting international regulatory requirements. The establishment of a USFDA-accredited facility indicates a proactive approach to gaining market access in these regions.

2Emerging Markets

Sava Healthcare Limited has expanded its footprint in emerging markets, including Africa, Latin America, and Southeast Asia. The company's international business division has a global presence across Canada, Ukraine, the CIS, Asia, and Africa, with both human and veterinary pharmaceuticals. While specific details regarding WHO prequalification are not provided, the company's adherence to international manufacturing standards positions it favorably for market access in these regions.

3Geographic Strategy

Sava Healthcare Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sava Healthcare Limited is in the process of establishing a USFDA-accredited manufacturing plant near Indore, India. This initiative aims to enhance the company's manufacturing capabilities and facilitate market access in the United States. Specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not readily available. However, the company's commitment to obtaining USFDA accreditation underscores its dedication to meeting stringent regulatory standards.

2WHO & EU GMP

Sava Healthcare Limited's manufacturing facility in Surendranagar, Gujarat, is WHO-GMP and PIC/s approved, indicating compliance with international manufacturing standards. While specific details regarding EU GMP certificates and EDQM status are not provided, the company's adherence to WHO-GMP standards suggests a commitment to meeting European regulatory requirements.

3CDSCO & Indian Regulatory

Sava Healthcare Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), ensuring compliance with Indian regulatory standards. The company's manufacturing facility in Surendranagar, Gujarat, is approved by WHO-GMP and PIC/s, reflecting adherence to international manufacturing standards. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not readily available.

Sava Healthcare Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sava Healthcare Limited operates in a competitive pharmaceutical industry, with key competitors in overlapping categories such as antimalarial and antiparasitic, cardiovascular, and respiratory products. While specific market share comparisons are not readily available, the company's focus on nasal drug delivery platforms and its global presence across Canada, Ukraine, the CIS, Asia, and Africa position it as a notable player in the market.

2Key Differentiators

Sava Healthcare Limited's key differentiators include its specialization in nasal drug delivery platforms, such as nasal sprays and dry powder inhalers, and its adherence to international manufacturing standards like WHO-GMP and PIC/s. The company's global footprint across diverse regions and its commitment to establishing a USFDA-accredited manufacturing facility further distinguish it in the competitive landscape.

3Strategic Position

Sava Healthcare Limited's current strategic direction encompasses generics, specialty pharmaceuticals, and Contract Development and Manufacturing Organization (CDMO) services. The company's focus on nasal drug delivery platforms and its expansion into global markets reflect a commitment to innovation and growth. The establishment of a USFDA-accredited manufacturing facility near Indore, India, indicates a proactive approach to enhancing manufacturing capabilities and market access.

Buyer Due Diligence Brief — Evaluating Sava Healthcare Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sava Healthcare Limited demonstrates a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and a global presence. The company's adherence to WHO-GMP and PIC/s standards, along with its plans to establish a USFDA-accredited manufacturing facility, underscore its commitment to quality and regulatory compliance. While specific export volumes and consistency metrics are not readily available, the company's strategic initiatives and global footprint suggest reliability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO-GMP Certification: Indicates compliance with World Health Organization Good Manufacturing Practices.
PIC/s Certification: Demonstrates adherence to Pharmaceutical Inspection Co-operation Scheme standards.
USFDA Accreditation: Confirms compliance with U.S. Food and Drug Administration regulations.

Frequently Asked Questions — Sava Healthcare Limited

How many pharmaceutical products does Sava Healthcare Limited export from India?

Sava Healthcare Limited exports 22 pharmaceutical products across 11 therapeutic categories. The top exports are Ivermectin ($2.3M), Apixaban ($1.4M), Bisoprolol ($1.1M), Fluticasone ($1.1M), Glucosamine ($868.3K). Total export value is $11.5M.

What is Sava Healthcare Limited's total pharmaceutical export value?

Sava Healthcare Limited's total pharmaceutical export value is $11.5M, based on 4,488 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Sava Healthcare Limited the #1 Indian exporter?

Sava Healthcare Limited is the #1 Indian exporter in 2 products: Ivermectin (27.0% market share), Asava (44.8% market share).

What therapeutic categories does Sava Healthcare Limited cover?

Sava Healthcare Limited exports across 11 therapeutic categories. The largest are Antimalarial & Antiparasitic (23.7%, 2 products), Cardiovascular (22.5%, 2 products), Respiratory (16.8%, 4 products).

Get Full Sava Healthcare Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.